Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

CheckMate 384 : essai clinique de phase 3b/4 évaluant nivolumab 480 mg toutes les 4 semaines (Q4S) vs nivolumab 240 mg toutes les 2 semaines (Q2S) chez les patients (pts) atteints d’un cancer bronchique non à petites cellules (CBNPC) avancé préalablement traité par nivolumab pendant une durée ≤ 12 mois

Autor: Sridhar K. Rabindran, I. Gore, E. Baldini, José Hureaux, Edward B. Garon, K. Jao, R. Harris, Niels Reinmuth, Paul Mitchell, L. Falchero, L. Zibdawi, Y. García, David R. Spigel, Silverio Ros, M. Wolf, Ang Li, Eric Pichon, Kenneth J. O'Byrne, P. Bidoli, E. Laack

Publikováno v: Revue des Maladies Respiratoires Actualités. 12:213-214

Introduction Nivolumab est approuve a la dose de 240 mg Q2S dans l’Union europeenne dans le traitement de 2e ligne du CBNPC avance. La modelisation pharmacocinetique dans diverses tumeurs predit que l’exposition, l’efficacite et la tolerance pe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5326ae1a78d13e0a3d21ab841ba89464
https://doi.org/10.1016/j.rmra.2019.11.470

Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program

Autor: Michaël Duruisseaux, Florian Huemer, Hannah Fabikan, Jeffrey Rothenstein, Malinda Itchins, Massimo Di Maio, Adrianus J. de Langen, Georg Pall, Florian Krenn, Katja Mohorcic, Alfredo Addeo, Gerald W. Prager, Christoph Weinlinger, Arschang Valipour, Okko-Sakari Kääränien, E. Laack, Stephen Clarke, Kristina Lamberg, Gudrun Absenger, Antonio Passaro, Antonio Calles, Ewald Wöll, Anders Vikström, Maximilian Hochmair, Oliver Illini, Alice Durand, Aurélie Swalduz, Achim Rittmeyer, Amanda Tufman, Shantanu Banerji, Michael Schumacher, Sayed M.S. Hashemi, Martin Wermke

Publikováno v: Illini, O, Hochmair, M J, Fabikan, H, Weinlinger, C, Tufman, A, Swalduz, A, Lamberg, K, Hashemi, S M S, Huemer, F, Vikström, A, Wermke, M, Absenger, G, Addeo, A, Banerji, S, Calles, A, Clarke, S, di Maio, M, Durand, A, Duruisseaux, M, Itchins, M, Kääränien, O-S, Krenn, F, Laack, E, de Langen, A J, Mohorcic, K, Pall, G, Passaro, A, Prager, G, Rittmeyer, A, Rothenstein, J, Schumacher, M, Wöll, E & Valipour, A 2021, ' Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program ', Therapeutic Advances in Medical Oncology, vol. 13 . https://doi.org/10.1177/17588359211019675
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Therapeutic Advances in Medical Oncology, 13. SAGE Publications Inc.
Therapeutic Advances in Medical Oncology
Therapeutic advances in medical oncology, vol. 13, pp. 1-17, 2021.

Introduction: Rearranged during transfection (RET) gene fusions are rare genetic drivers in non-small cell lung cancer (NSCLC). Selective RET-inhibitors such as selpercatinib have shown therapeutic activity in early clinical trials; however, their ef

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccb6b16aa3c3964be405e128fd323706
https://doi.org/10.1177/17588359211019675

P2.01-79 Afatinib in EGFR Mutation-Positive (EGFRm+) NSCLC Harbouring Uncommon Mutations: Experience in ‘Real-World’ Clinical Practice

Autor: Y. Wu, W. M. Brückl, Christopher M. Hoffmann, E. Laack, C. Zhou

Publikováno v: Journal of Thoracic Oncology. 14:S670-S671

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d9676deb4f8d837ef7e9c638daf06a4f
https://doi.org/10.1016/j.jtho.2019.08.1422

Sequential treatment with afatinib followed by 3rd generation EGFR-TKI – subgroup analysis of the GIDEON trial: A prospective non-interventional study (NIS) in EGFR mutated NSCLC patients in Germany

Autor: E. Laack, Rudolf M. Huber, W. M. Brückl, Christopher M. Hoffmann, B. Hermes, Martin Reck, A. Schueler, Justyna Rawluk

Publikováno v: Annals of Oncology. 30:v627

Background Afatinib and osimertinib both inhibit sensitizing EGFR mutations (deletion 19 and L858R). In addition, osimertinib is highly active against the most frequent resistance mutation (∼60%) T790M and was originally registered for these patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3438a9b049c8f72d64416939ab0b24ef
https://doi.org/10.1093/annonc/mdz260.049